Myriad Sep 6, 2022 UK's MHRA Approves Adjuvant Lynparza for BRCA-Mutant, High-Risk Early Breast Cancer Aug 26, 2022 Myriad Genetics Gets Expanded Coverage for BRACAnalysis CDx in Japan Aug 24, 2022 Myriad Genetics, Clarified Precision Medicine Team up on Molecular Tumor Board Service Aug 4, 2022 Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer Jun 24, 2022 Myriad Genetics Partners with Epic Systems to Make Test Results Available in EMR May 12, 2022 ESMO Advances Biomarker Framework to Guide Cancer Therapy De-Intensification, Decision-Making Premium Mar 17, 2022 Lynparza Survival Benefit, FDA Approval in Early-Stage Breast Cancer Could Broaden Genetic Testing Premium Mar 14, 2022 Myriad Genetics Launches New Comprehensive Suite of Cancer Tests With Research Registry Premium Sep 7, 2021 Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay Jun 5, 2021 Myriad Genetics Recalibrates Breast Cancer PRS for All Ancestries in Anticipation of Broader Launch Premium Jun 4, 2021 In Brief This Week: Oncocyte, Qiagen, Myriad Genetics, Iaso Biotherapeutics Apr 27, 2021 Castle Biosciences Acquires Myriad Genetics' MyPath Melanoma Test, Lab for $32.5M Mar 26, 2021 In Brief This Week: Mirati Therapeutics, Gilead, Natera, Actinium Pharmaceuticals, Myriad Genetics Mar 24, 2021 Intermountain Gets National Stage, Myriad Adds Tumor Profiling Panel With Combined Test Offering Premium Mar 2, 2021 Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service Jan 22, 2021 In Brief This Week: Myriad Genetics, Diaceutics, Agios, Precipio, Lantern Pharma, Guardant Health Jan 12, 2021 JP Morgan Healthcare, Day 1: Merck KGaA, Mirati, Agios, Tempus, Bristol Myers, Amgen, and More Jan 11, 2021 Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan Jan 8, 2021 In Brief This Week: Genentech, Myriad Genetics, Merus, Ambrx, and More Dec 9, 2020 Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project Load More Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
